Abstract 4142
Background
AntiPD1 Nivolumab (N) or Pembrolizumab (P) are an option for first line treatment in metastatic melanoma (MM) but predictive factors of efficacy are needed to choose between them or other treatment (antiPd1+AntiCTLA4, BRAF+MEK inhibitors (BMEi) for BRAF mutated melanoma). Many studies suggest that LDH, ECOG PS, tumor burden can identify BRAF mutated MM patients (pt) in which BMEi show better outcome. Similar data are not available for N or P in first line. We evaluate pt treated with N or P in first line in order to verify if these factors or other factors can be applyed also to antiPD1.
Methods
A retrospective multicenter study was conducted in 13 Italian Oncology Centers, evaluating MM pt treated with N or P in first line from 2016. Endpoints were OS and PFS, Kaplan Mayer and Cox regression were applied for survival analysis.
Results
236 pt were analyzed (51% treated with N, 7% BRAF mutated). ECOG PS was 0 in 169 pt, number of metastatic sites (Nu) was less then 3 in 135 pt, in 88 pt there were not visceral metastasis (Vi), LDH was normal in 141 pt, ratio between baseline neutrophils and total leukocytes count (Fr) was less then 0.7 in 152 pt: in univariate analysis, all this factors resulted significantly associated with better OS (all p < 0.0003) and PFS (all p < 0.003), the only exeption were pt with Nu less then 3 that resulted not signficantly different in PFS then pt with higher Nu (p 0.13). In multivariate analysis all these factors were confirmed as significantly associated with better PFS and OS (all p < 0.03), with the exeption of Nu (p 0.22) A score was counted for every pt considering the number of favorable baseline factors present (normal LDH, ECOG PS 0, Vi 0, Fr < 0.7) 18 months-PFS was 69% in pt with all 4 favorable factors vs 41% in pt without favorables factors (p value 0.0029). 18 months-OS was 90% in pt with all four favoreble factors vs 48% in pt without favorables factors (p value<0.0001).
Conclusions
ECOG PS 0, normal LDH, Fr < 0.7, absent Vi are indipendent baseline factors associated with favorable PFS and OS of MM pt treated with N or P in first line (instead of Nu – that was found relevant for BMEi in other study). Subgroup with all these factors has a better prognosis. These data can help first line treatment choice and should be evaluated prospectively.
Clinical trial identification
Legal entity responsible for the study
Italian Melanoma Intergroup I.M.I.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
R. Marconcini: Consultancy, Advisory board, Honoraria for speaking: BMS, MSD, Novartis, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
5720 - Evaluation of stemness and proliferation of human breast cancer stem cells (ALDH+) supplemented with heat-activated TGF-beta1 in the secretomes of stem cells from human exfoliated deciduous teeth (SHED)
Presenter: Septelia Wanandi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4844 - Estrogen-related receptor _ as a potential molecular target for endometrial cancer therapy
Presenter: TETSUYA KOKABU
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1200 - Good tolerability and limited target-specific tissue distribution of an anti-L1CAM antibody administered to cynomolgus monkey indicates favorable safety profile of L1CAM-targeting therapies
Presenter: Jacques Gaudreault
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2905 - Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma
Presenter: Anne Jouinot
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2597 - Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study
Presenter: Juan Manuel O'Connor
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2663 - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
Presenter: Julien Taieb
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1670 - Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study
Presenter: Takeshi Kawakami
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1088 - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD
Presenter: thomas Aparicio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2548 - Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer
Presenter: Toshiki Masuishi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3244 - Regorafenib for metastatic colorectal carcinoma: a registry-based analysis
Presenter: Katerina Kopeckova
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract